Invention Grant
- Patent Title: Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
-
Application No.: US17352915Application Date: 2021-06-21
-
Publication No.: US11472858B2Publication Date: 2022-10-18
- Inventor: Yihong Yao , Jiaqi Huang , Shigui Zhu , Wei Zhu , Xin Yao , Zhiyuan Li , Li Zhang , Lin Zhu , Anyun Ma , Yutian Wei , Yanfeng Li , Qingxia Wang , Jiaping He
- Applicant: CELLULAR BIOMEDICINE GROUP HK LIMITED
- Applicant Address: CN Hong Kong
- Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
- Current Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
- Current Assignee Address: CN Hong Kong
- Agency: Leason Ellis LLP
- Priority: CN201710069569.7 20170208
- Main IPC: C07K7/00
- IPC: C07K7/00 ; C07K14/725 ; A61P35/00 ; A61K35/17 ; C07K14/705 ; C07K16/28 ; C12N7/00 ; C12N15/86 ; C07K19/00 ; C12N5/10 ; C12N15/62 ; A61P35/02 ; A61K9/00 ; A61K38/00 ; A61K39/00
Abstract:
Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
Public/Granted literature
Information query
